Abstract
Current antiretroviral therapy (ART) efficiently controls HIV-1 replication but fails to eradicate the virus. Even after years of successful ART, HIV-1 can conceal itself in a latent state in long-lived CD4(+) memory T cells. From this latent reservoir, HIV-1 rebounds during treatment interruptions. Attempts to therapeutically eradicate this viral reservoir have yielded disappointing results. A major problem with previously utilized activating agents is that at the concentrations required for efficient HIV-1 reactivation, these stimuli trigger high-level cytokine gene expression (hypercytokinemia). Therapeutically relevant HIV-1-reactivating agents will have to trigger HIV-1 reactivation without the induction of cytokine expression. We present here a proof-of-principle study showing that this is a possibility. In a high-throughput screening effort, we identified an HIV-1-reactivating protein factor (HRF) secreted by the nonpathogenic bacterium Massilia timonae. In primary T cells and T-cell lines, HRF triggered a high but nonsustained peak of nuclear factor kappa B (NF-kappaB) activity. While this short NF-kappaB peak potently reactivated latent HIV-1 infection, it failed to induce gene expression of several proinflammatory NF-kappaB-dependent cellular genes, such as those for tumor necrosis factor alpha (TNF-alpha), interleukin-8 (IL-8), and gamma interferon (IFN-gamma). Dissociation of cellular and viral gene induction was achievable, as minimum amounts of Tat protein, synthesized following application of a short NF-kappaB pulse, triggered HIV-1 transactivation and subsequent self-perpetuated HIV-1 expression. In the absence of such a positive feedback mechanism, cellular gene expression was not sustained, suggesting that strategies modulating the NF-kappaB activity profile could be used to selectively trigger HIV-1 reactivation.
MeSH Terms
Bacterial Proteins/immunology,isolation & purification,pharmacology
Cell Line
Cells, Cultured
Gene Expression Regulation, Viral
HIV Infections/genetics,immunology,virology
HIV-1/drug effects,genetics,physiology
Humans
NF-kappa B/genetics,immunology
Oxalobacteraceae/chemistry,immunology
T-Lymphocytes/drug effects,immunology,microbiology,virology
Transcriptional Activation
Virus Activation
Virus Latency
Chemicals
Bacterial Proteins
NF-kappa B
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Wolschendorf Frank
Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
Duverger Alexandra
Jones Jennifer
Wagner Frederic H
Huff Jason
Benjamin William H
Saag Michael S
Niederweis Michael
Kutsch Olaf
References (32)
32 references, click to expand
-
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.
Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8869-73
PMID: 9671771
-
Determinants of the establishment of human immunodeficiency virus type 1 latency.
J Virol. 2009 Apr;83(7):3078-93
PMID: 19144703
-
Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines.
J Exp Med. 1998 Jul 6;188(1):83-91
PMID: 9653086
-
Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1.
J Virol. 2007 Jun;81(11):6043-56
PMID: 17376917
-
Massilia jejuensis sp. nov. and Naxibacter suwonensis sp. nov., isolated from air samples.
Int J Syst Evol Microbiol. 2010 Aug;60(Pt 8):1938-1943
PMID: 19783608
-
Massilia aerilata sp. nov., isolated from an air sample.
Int J Syst Evol Microbiol. 2008 Jun;58(Pt 6):1422-5
PMID: 18523189
-
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.
Nat Med. 2003 Jun;9(6):727-8
PMID: 12754504
-
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.
Nat Med. 2000 Jul;6(7):757-61
PMID: 10888923
-
Latent reservoirs of HIV: obstacles to the eradication of virus.
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):10958-61
PMID: 10500107
-
Massilia aurea sp. nov., isolated from drinking water.
Int J Syst Evol Microbiol. 2006 Oct;56(Pt 10):2449-2453
PMID: 17012578
-
In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency.
Nat Med. 1995 Dec;1(12):1284-90
PMID: 7489410
-
Dynamics of HIV-1 recombination in its natural target cells.
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4204-9
PMID: 15010526
-
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.
Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13193-7
PMID: 9371822
-
Valproic acid and HIV-1 latency: beyond the sound bite.
Retrovirology. 2005 Sep 19;2:56
PMID: 16168066
-
Optimization of HIV-1 infectivity assays.
Biotechniques. 2007 Nov;43(5):589-90, 592, 594
PMID: 18072587
-
Targeting HIV reservoirs with valproic acid.
Hopkins HIV Rep. 2005 Sep;17(5):8-9
PMID: 16419304
-
Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells.
Mol Cell Biol. 2002 Feb;22(3):724-36
PMID: 11784850
-
Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency.
J Virol. 2002 Sep;76(17):8776-86
PMID: 12163598
-
The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation.
Science. 2002 Nov 8;298(5596):1241-5
PMID: 12424381
-
Transcriptional interference antagonizes proviral gene expression to promote HIV latency.
Cell Host Microbe. 2008 Aug 14;4(2):123-33
PMID: 18692772
-
Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes.
J Virol. 2004 Jun;78(12):6122-33
PMID: 15163705
-
Encoding NF-kappaB temporal control in response to TNF: distinct roles for the negative regulators IkappaBalpha and A20.
Genes Dev. 2008 Aug 1;22(15):2093-101
PMID: 18676814
-
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.
Lancet. 2005 Aug 13-19;366(9485):549-55
PMID: 16099290
-
Circuitry of nuclear factor kappaB signaling.
Immunol Rev. 2006 Apr;210:171-86
PMID: 16623771
-
Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.
J Infect Dis. 2002 Nov 15;186(10):1403-11
PMID: 12404155
-
Characteristics of Massilia timonae and Massilia timonae-like isolates from human patients, with an emended description of the species.
J Clin Microbiol. 2003 Jan;41(1):192-6
PMID: 12517847
-
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
Nature. 1997 May 8;387(6629):183-8
PMID: 9144289
-
Massilia timonae gen. nov., sp. nov., isolated from blood of an immunocompromised patient with cerebellar lesions.
J Clin Microbiol. 1998 Oct;36(10):2847-52
PMID: 9738031
-
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.
Nat Med. 1999 Jun;5(6):651-5
PMID: 10371503
-
Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough.
Cell Host Microbe. 2008 Aug 14;4(2):134-46
PMID: 18692773
-
High throughput drug screening for human immunodeficiency virus type 1 reactivating compounds.
Assay Drug Dev Technol. 2007 Apr;5(2):181-89
PMID: 17477827
-
T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication.
Biotechniques. 2006 Jan;40(1):91-100
PMID: 16454046